Sarepta Therapeutics Income Statement
SRPT / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
Sarepta Therapeutics reported $2.2B in revenue and $713M in net loss for FY2025. Revenue has grown at a 63.6% compound annual rate over the past 11 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2B | $1.9B | $1.2B | $540.1M | $701.9M | $301.0M | $154.6M | $301.0M | $154.6M | $5.4M | $1.3M | $9.8M | - | - | - |
| Cost of Revenue | $25.5M | - | - | - | - | - | - | - | - | $130.0K | - | - | - | - | - |
| SG&A Expense | $491.7M | $557.9M | $481.9M | $317.9M | $282.7M | $207.8M | $122.7M | $207.8M | $122.7M | $83.7M | $75.0M | $49.3M | $31.6M | $14.6M | $16.1M |
| R&D Expense | $1.5B | $804.5M | $877.4M | $722.3M | $771.2M | $401.8M | $90.6M | $46.2M | $166.7M | $188.3M | $146.4M | $94.2M | $72.9M | $52.4M | $66.9M |
| Operating Income | -$699.8M | $218.1M | -$267.8M | -$564.2M | -$459.7M | -$343.6M | -$171.6M | -$343.6M | -$171.6M | -$266.7M | -$220.2M | -$133.8M | -$90.3M | -$29.7M | -$35.9M |
| Interest Expense | $1.9M | -$18.4M | -$22.0M | $59.9M | $63.5M | $33.7M | $5.8M | $33.7M | $5.8M | $1.9M | $1.4M | $100.0K | $100.0K | $100.0K | $100.0K |
| Income Tax | $11.2M | $25.5M | $15.9M | $1.1M | -$168.0K | -$692.0K | $2.1M | -$692.0K | $2.1M | - | - | - | - | - | - |
| Net Income | -$713.4M | $235.2M | -$536.0M | -$554.1M | -$418.8M | -$361.9M | -$50.7M | -$361.9M | -$50.7M | -$267.3M | -$220.0M | -$135.8M | -$112.0M | -$121.3M | -$2.3M |
| EPS (Basic) | -$5.80 | -$8.03 | -$5.15 | -$7.11 | - | - | - | - | $1.53 | - | - | - | - | -$0.78 | -$0.02 |
| EPS (Diluted) | -$5.80 | -$8.03 | -$5.15 | -$7.11 | -$9.71 | -$5.46 | -$0.86 | -$5.49 | $1.50 | -$3.39 | - | - | - | -$0.78 | -$0.02 |
| Shares Outstanding | 96.9M | 93.7M | 88.0M | 87.1M | 79.4M | 75.2M | 71.1M | 64.8M | 54.8M | 45.6M | 42.3M | 40.0M | 33.9M | 23.6M | 21.6M |
| Operating Margin | -31.8% | 11.5% | -21.5% | -104.5% | -65.5% | -114.1% | -111.0% | -114.1% | -111.0% | -4920.3% | - | - | - | - | - |
| Profit Margin | -32.5% | 12.4% | -43.1% | -102.6% | -59.7% | -120.2% | -32.8% | -120.2% | -32.8% | -4930.2% | - | - | - | - | - |